Form 4: Adaptive Biotechnologies Exec Trades Shares

Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp, reported a series of stock transactions involving both acquisitions and dispositions of common stock.

Summary

• Julie Rubinstein, President and COO of Adaptive Biotechnologies Corp, engaged in multiple stock transactions between April 9, 2026, and April 13, 2026.
• These transactions included the acquisition of common stock at $7.27 per share and $8.46 per share, as well as the disposition of common stock at various weighted average prices ranging from $12.43 to $14.62.
• The acquisitions were made under a Rule 10b5-1 trading plan adopted on November 18, 2025.
• Following these transactions, Rubinstein's beneficial ownership of common stock changed, with a net decrease in directly held shares.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative sentiment due to the significant volume of stock sales by a key executive, despite being executed under a pre-planned trading strategy.

Positives

• Transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less market-sensitive trading activity.
• Acquisition of shares at lower prices ($7.27 and $8.46) could be viewed positively if the stock price subsequently increases.

Negatives

• Significant disposition of common stock by a key executive, potentially signaling a lack of confidence or a need for personal liquidity.
• The weighted average sale prices indicate that shares were sold at prices significantly higher than the acquisition prices, realizing gains but reducing executive holdings.

Risks

• The disposition of a substantial number of shares by a high-ranking executive could be interpreted negatively by the market, potentially impacting investor sentiment.
• While executed under a 10b5-1 plan, the volume of sales might still raise questions about the executive's long-term conviction in the company's prospects.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports past transactions.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
• The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common event for executives needing to diversify or manage personal finances. However, the volume and timing relative to company news can influence market perception. Adaptive Biotechnologies operates in the rapidly evolving biotechnology sector, where executive confidence is closely watched.

Stakeholder Impact

• Shareholders: May view the executive's stock sales negatively, potentially impacting share price due to reduced insider confidence.
• Employees: May interpret the sales as a sign of executive concerns about future company performance.
• Management: The sales reduce the direct beneficial ownership of a key executive.

Next Steps

• The reporting person may be required to provide further details on specific sale prices upon request from the SEC, Adaptive Biotechnologies Corporation, or security holders.

Key Dates

Recommendation

The filing reports insider stock sales under a 10b5-1 plan. While significant sales by a COO can be a negative signal, the pre-planned nature mitigates immediate concern. Without other performance-related information, a 'hold' recommendation is prudent, suggesting investors monitor future company disclosures and stock performance.

Keywords

Form 4, SEC Filing, Insider Trading, Stock Transaction, Adaptive Biotechnologies Corp, ADPT, Julie Rubinstein, Rule 10b5-1, Common Stock, Executive Compensation